Biohaven (BHVN) vs Maravai LifeSciences (MRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Maravai LifeSciences (MRVI) has outperformed Biohaven (BHVN) over the past year, gaining 86.1% versus a gain of 27.9%. Biohaven is the larger company by market cap ($1.87 billion vs $1.81 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHVN | MRVI |
|---|---|---|
| Share price | $12.39 | $6.98 |
| Market cap | $1.87B | $1.81B |
| 1-day change | -9.23% | -2.92% |
| YTD return | +9.74% | +114.77% |
| 1-year return | +27.86% | +86.13% |
| 5-year return | — | -83.18% |
| EPS (TTM) | $-3.77 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $185.74M |
| Revenue growth (YoY) | — | -28.34% |
| Net income (latest FY) | $-738.82M | $-130.77M |
| Gross margin | — | 18.30% |
| Operating margin | — | -115.89% |
| Net margin | — | -70.41% |
| 52-week high | $18.24 | $9.42 |
| 52-week low | $8.03 | $2.80 |
| Distance from 52-week high | -32.07% | -25.90% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +102.82% | +38.11% |
| Average volume | 3.24M | 2.72M |
| Shares outstanding | 151.06M | 149.25M |
| Employees | 274 | 410 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRVI has outperformed BHVN by 58.3 percentage points over the past year.
About Biohaven
BHVN stock →Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees
About Maravai LifeSciences
MRVI stock →Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.
Health Care · Biotechnology: Pharmaceutical Preparations · 410 employees
BHVN vs MRVI FAQ
Which is bigger, Biohaven or Maravai LifeSciences?
Biohaven (BHVN) is larger, with a market capitalization of $1.87B compared with $1.81B for Maravai LifeSciences (MRVI).
Which stock has performed better over the past year, BHVN or MRVI?
MRVI returned +86.13% over the past 12 months, compared with +27.86% for BHVN (price return, excluding dividends). Past performance does not predict future results.
Are Biohaven and Maravai LifeSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.